Kenanga Investment Bank Berhad (Bursa Malaysia: 6483) has launched what it says are the world’s first structured warrants linked to the Hang Seng Biotech Index, giving Malaysian investors a new listed route into Hong Kong’s biotechnology and healthcare sector.
Why it matters: The Hang Seng Biotech Index gained 64.5% in 2025 — significantly outperforming Hong Kong’s broader indexes — making it one of the standout growth stories in Asian equities last year. Kenanga’s bet is that Malaysian retail and semi-institutional investors want a listed way into that theme without needing direct access to Hong Kong-listed stocks, and that being first to market with that product matters in a warrants business where Kenanga already holds an outsized share.
Fast facts
- Issuer: Kenanga Investment Bank Berhad (Bursa Malaysia: 6483), under its NagaWarrants brand
- New products: HSBIO-CAA (0661AA) and HSBIO-HBA (0661BA)
- Underlying index: Hang Seng Biotech Index (HSBIO) — tracks 30 of the largest biotech and healthcare companies listed in Hong Kong
- 2025 index performance: +64.5% for the year, rising more than 80% at its peak, per Kenanga
- Launch venue: the 11th Belt and Road Summit, Hong Kong, September 9, 2026
- Kenanga’s existing market share: roughly 53% of average daily trading volume and 51% of average daily trading value across all HSI structured warrants on Bursa Malaysia in 2025, according to the bank
What was launched, and where
The two new warrants trade under Kenanga’s NagaWarrants brand, which already offers instruments linked to the Hang Seng Index, the Hang Seng China Enterprises Index, and the Hang Seng TECH Index. HSBIO is the newest addition to that lineup, and Kenanga says it’s the first time the biotech index has been made accessible through a listed structured warrant format anywhere.
The launch ceremony took place at the 11th Belt and Road Summit in Hong Kong on September 9, 2026, bringing together representatives from Kenanga and Hang Seng Indexes Company Limited, the entity that maintains and licenses the index.
Why the underlying index is drawing attention
The Hang Seng Biotech Index tracks 30 of the largest biotechnology and healthcare companies listed in Hong Kong. In 2025, it gained 64.5%, outperforming the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng TECH Index by a wide margin, and rose more than 80% at its peak during the year — Kenanga attributes that run to growing investor interest in China’s biotechnology sector, driven by demographic shifts, rising healthcare demand, and continued medical innovation.
That momentum has already built out a broader ecosystem around the index: listed futures contracts and exchange-traded funds tracking HSBIO now hold more than HKD11 billion in assets under management, according to Kenanga. The new structured warrants are a way to extend that existing institutional interest down to Malaysia’s retail investor base.
Why Kenanga specifically
Kenanga isn’t a new entrant to Hong Kong-linked structured products — it’s already one of the dominant issuers in this space on Bursa Malaysia. The company says it accounted for roughly 53% of the average daily trading volume and 51% of the average daily trading value of all HSI structured warrants traded on Bursa Malaysia in 2025, a scale that gives it a head start in distribution and investor familiarity as it expands into a new underlying index.
Datuk Chay Wai Leong, Group Managing Director of Kenanga Investment Bank Berhad, framed the launch as part of a broader product-innovation strategy: “Being the first to introduce HSBIO-linked structured warrants reflects our commitment to staying at the forefront of product innovation,” he said, adding that NagaWarrants aims to “identify emerging opportunities and translate them into accessible investment solutions.”
Philip Lim Kuok Wei, Kenanga’s Head of Equity Markets and Group Head of Equity Derivatives, tied the launch to a shift in what investors are asking for. “We are seeing growing interest in targeted exposures beyond broad market benchmarks, with biotechnology emerging as one of Asia’s most dynamic growth sectors,” he said, calling the HSBIO warrants “the first in a series of initiatives” the bank plans in this direction.
Recent recognition
The launch follows Kenanga being named Best Warrants Issuer Malaysia 2026 by Global Banking and Finance Review — an industry award that, alongside the bank’s existing HSI warrants market share, forms part of the company’s own case for why it was positioned to be first to market with HSBIO.
Zoom out
Structured warrants are leveraged instruments — they give holders the right, not the obligation, to buy or sell an underlying asset at a set price before expiry, letting investors take amplified, time-limited exposure without committing the full capital a direct stake would require. That makes them a useful lens on investor sentiment: when an issuer bets on a new underlying index, it’s a signal about where retail demand is heading next. Kenanga is betting Malaysian investors want more targeted access to China’s biotech growth story specifically, not just broad Hong Kong market exposure — a reasonable read after HSBIO’s 2025 run, though it’s worth remembering that the index’s outsized gains also mean outsized volatility, a risk structured warrants amplify rather than soften.
